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Metallothionein 3 (MT-3), also known as growth inhibitory factor (GIF), exhibits a neuroinhibitory activity. Our lab and others
have previously shown that this biological activity involves interacting protein partners in the brain. However, nothing speciﬁc is
yet known about which of these interactions is responsible for the GIF activity. In this paper, we are reporting upon new proteins
found interacting with MT-3 as determined through immunoaﬃnity chromatography and mass spectrometry. These new partner
proteins—Exo84p, 14-3-3 Zeta, α and β Enolase, Aldolase C, Malate dehydrogenase, ATP synthase, and Pyruvate kinase—along
with those previously identiﬁed have now been classiﬁed into three functional groups: transport and signaling, chaperoning and
scaﬀolding, and glycolytic metabolism. When viewed together, these interactions support a proposed model for the regulation of
the GIF activity of MT-3.
1.Introduction
In a comparative study, Uchida et al. found that brain extract
from Alzheimer’s disease (AD) patient had an enhanced
neurotrophic eﬀect when compared to normal brain extract
[1]. This was subsequently attributed to the reduction of a
protein originally called, growth inhibitory factor (GIF). The
latter was ﬁrst thought to be involved in the formation of
the senile plaques, which leads to the enhanced sprouting
and the exhaustion of the neurons and, therefore, increases
the susceptibility of the neurons to exocitotoxic substances
[2]. However, in a followup study, a correlation was found
between the reduction of the GIF activity and the presence
of neuroﬁbrillary tangles and not with the senile plaques
[3]. Further isolation, puriﬁcation, and sequencing of the
GIF revealed that it belonged to the metallothionein (MT)
protein family, the third isoform isolated and puriﬁed in this
family, thus the name metallothionein-3 (MT-3) [3].
MTs are a class of small (6-7kDa) cysteine-rich (30%)
proteins binding both essential (Cu+ and Zn2+) and non-
essential (Cd2+,A g + and Hg2+) metal ions [4]. While metal
binding is very tight, there is a facile metal exchange between
MTs and other metalloproteins [5]. In mammalian species,
four isoforms are currently known, which are designated
a sM T - 1 ,2 ,3 ,a n d4[ 6]. MT-1 and 2 are expressed in
almost every organ, particularly high in the kidney and liver
and both exhibit similar properties as far as metal-binding
characteristics are concerned. MT-3 is expressed mainly in
the brain, though some studies have reported ﬁnding MT-3
in the kidney and some cancer cells [7]. MT-4 is expressed in
certain stratiﬁed tissues [8].
Since the discovery of MT-1 and MT-2, there have
been numerous publications describing the biochemical
characteristics and possible function of these isoforms
[9]. Although the essential physiological functions remain
elusive, MT’s have been shown to be involved in these vital
processes: (1) the modulation of free oxygen radicals and
nitric oxide [10], (2) apoptosis [11], and (3) homeostasis of
heavy metals [4]. All three physiological processes play a key
role in several diseases [9].
The binding of metal ions occurs, speciﬁcally through
cysteine thiolate bonds, in two separate domains. The N-
terminaldomain,calledβ-domain,binds3divalentmetalsin
aM e 3S9 tetrahedral coordination. The C-terminal domain,2 International Journal of Alzheimer’s Disease
called α-domain, binds 4 divalent metals in a Me4S11
tetrahedral coordination [12, 13]. While MT-1 and MT-2
have been shown to be inducible at the transcriptional level
by the very heavy metals that they bind, such as Cd, Cu,
and Zn [14], MT-3 is not induced by metal ions. Indeed,
MT-3 and MT-1 respond diﬀerentially to zinc deprivation
of cells in culture with only MT-1 being downregulated in
these cells [15] .T h u s ,i ti sr e a s o n a b l et oc o n c l u d et h a tM T - 3
is not involved in metal ion homeostasis, as both the MT-1
and MT-2 isoforms appears to be [4, 14].
Studies have shown that the MT-3 β-domain was suﬃ-
cient to exhibit the GIF activity [16–18]. However, MT-3 by
itself does not exhibit GIF activity when added to neuronal
cell cultures. This activity is only expressed when combined
with brain extracts [17]. From this, one can conclude that
the inhibitory activity is invoked by speciﬁc interaction(s)
between MT-3 and other component(s) in the brain extract.
Indeed, we and others have previously described some other
components in the brain interacting with MT-3 [19–23].
Immunoaﬃnity chromatography is a highly sensitive
and selective method for the isolation of target proteins
and for the identiﬁcation of protein-protein interactions
[20]. The results from these experiments presented in this
current paper represent a signiﬁcant extension with 7 new
proteins positively identiﬁed interacting with MT3, along
with the 5 proteins identiﬁed in the preliminary mass spectra
analysis of the bands in the tryptic digested gel [21]. Selected
protein binding partners identiﬁed in Lahti et al. [21]w e r e
validated using antisera available for the associated proteins.
A recent paper appeared by Chung et al. [24], which showed
the release of MT-1 and 2 from astrocytes and uptake in
neurons in response to brain injury. The mechanism of
the secretion of these two MT isoforms, however, is quite
distinct from the mechanism proposed here for MT-3. In
this paper, we present a detailed description of new proteins
found interacting with MT-3, which leads us to propose a
new model for the secretion of MT-3 from the astrocytes
and uptake in neurons, thus providing the ﬁrst mechanistic
description of its neuroinhibitory activity.
2.MaterialsandMethods
2.1. Protein Extraction. Whole mouse (8–10 weeks) brains
(Swiss Webster, Pel-Freez) were used for total protein extrac-
tion. The brains were homogenized at a ratio of 2:1 (v/w)
in 10mM MOPS, 10mM NaCl, pH 7.0 containing 1mM
PMSF and EDTA-free protease inhibitor cocktail (Roche).
The homogenate was then centrifuged at 30000g, 4◦Cf o r
30min. The supernatant thus obtained was used for the MT-
3 protein complex puriﬁcation.
2.2. Aﬃnity Chromatography. Aﬃ-Gel Hz (Biorad) was used
to immobilize the MT-3 antibody previously puriﬁed [25].
The supernatant was applied to the column and incubated
overnight. The nonbound fraction was then thoroughly
washed with the homogenization buﬀer. The column was
then rinsed with 10mM MOPS, 150mM NaCl pH 7.0
containing 1mM PMSF and the protease inhibitor cocktail
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Figure 1: Washing steps for the immunoaﬃnity column. After
loading the column was washed with diﬀerent salt concentration
until no protein was eluted (absorbance at 280nm).
until no protein was eluted from the column (see Figure 1).
The MT-3 protein complex was then chaotropically eluted
using 10mM MOPS, 3M NaSCN, pH 7.0. The MT-3
protein complex was then concentrated using a spin-ﬁlter
with MWCO of 3kDa and the buﬀer exchanged to the
homogenization buﬀer.
2.3. SDS-PAGE and In-Gel Trypsin Digestion. The MT-
3 protein complex fraction was then SDS-paged using
NuPAGE Novex 4–12% Bis-Tris gel and run for 30min at
200V using MES-SDS buﬀer (Invitrogen). The gel was then
silver-stained using an enhanced silver stain kit (Biorad).
Protein bands were excised using the Investigator Pro-
prep from Genomics Solutions. The digestion of the band
was done according to a modiﬁed procedure [26]. Brieﬂy,
bands were excised and destained using 30mM potassium
ferricyanide and 100mM sodium thiosulphate, washed with
Milli-Q and then with 100% acetonitrile, followed by
SpeedVac for 30min. Trypsin (sequence-grade modiﬁed
porcine, Promega) was then added to a ﬁnal concentration
of 12.5ng/μL in ice-cold 50mM ammonium bicarbonate
containing 5mM CaCl2. The mixture was incubated on ice
for 1 hour and then at 37◦C overnight. The supernatant was
removed and the gel slices washed once with 20mM ammo-
nium bicarbonate for 20min and then pooled together.
The gel slices were washed three times with 30μL of 50%
acetonitrile/5%formicacidfor20mineach,andthenpooled
with the previous supernatant.
The collected supernatant was then SpeedVac to near
dryness and subjected to cysteine reduction and alkylation.
This was done by rehydration in 10mM DTT/100mM
NH4HCO3 at 56◦C for 45min. After cooling the sam-
ple to room temperature, alkylation was conducted using
freshlymade55mMiodoacetamide,100mMNH4HCO3,for
30min at room temperature in dark.International Journal of Alzheimer’s Disease 3
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Figure 2: 4–12% SDS-PAGE of the fractions collected from
the immunoaﬃnity chromatography of the normal mouse brain
homogenate. Lane 1: Markers, Lane 2: fractions collected with 3M
NaSCN, 10mM MOPS, pH 7.6.
2.4. Mass Spectrometry Analysis. MALDI-TOF data were
collected on a Biﬂex III instrument (Bruker Daltonics).
Full mass scans were collected, in the positive ion mode
between m/z 500 and 3500, for the peptide mixtures of
each sample placed on an anchor chip target. Each peak
list of measured peptide masses was then used to search
the National Center of Biotechnology Information (NCBI)
sequence database for protein identiﬁcation using Mascot
(http://www.matrixscience.com/). Searches were performed
allowing modiﬁcations that included methionine oxidation
and carbamidomethyl addition, as well as up to 1 missed
cleavage site and up to 250ppm mass error. Only hits with
P<. 05 were considered positive hits, where P is the
probability that the observed match is a random event.
MS-MS experiments were preformed on a linear ion
trap (LTQ, Thermo Electron Corp., San Jose, CA) using
nanoscale microcapillary reversed-phase liquid chromatog-
raphy electrospray ionization tandem mass spectrometry
(LC-MS/MS). Peptide mixtures were auto sampled on a
ParadigmMS4system(MichromBioresources,Inc.,Auburn,
CA). Samples were desalted and concentrated on a Paradigm
Platinum Peptide Nanotrap precolumn (0.15 × 50mm,
Michrom Bioresources, Inc.) and subsequently on a fused
silica microcapillary column (75μm i. d.) packed in-house
with Magic C18AQ reversed-phase material on a ﬂow
splitter (Michrom Bioresources, Inc.) at a ﬂow rate of
approximately 250NL/min. The samples were subjected to a
60min (10–40% ACN) gradient and directly eluted into the
microcapillary column set to 2.0kV. The LTQ was operated
in the positive-ion mode using data-dependent acquisition
methods initiated by a survey MS scan, which was followed
by MS/MS (collision energy of 29%) on the 4 most abundant
ions detected in the survey scan. M/Z values selected in
the survey scan for MS/MS were excluded for subsequence
MS/MS for 30sec. The signal intensity threshold for an ion
to be selected for MS/MS was set to a lower limit of 1000.
MassspectrawereanalyzedusingBioWorksSeQuestAnalysis
Software package (ABI, Inc., Foster City, CA). Proteins that
contained peptides with Sequest cross-correlation scores
greater than 2 and contained 2 or more peptides were further
examined manually.
3. Results
The analysis of the MT-3 protein complex(es) with SDS-
PAGE revealed the presence of about 16 bands (Figure 2).
Twelve proteins have been conﬁdently identiﬁed thus far
using MALDI-TOF and MS/MS. All the proteins reported
previously to interact with MT-3 [19, 21]w e r er e p r o d u c i b l y
detected. New proteins found in the current study include:
Exocyst complex component 8 (Exo84p), α and γ-enolase,
14-3-3 zeta, Malate dehydrogenase, Fructose-biphosphate
aldolase 3, and ATP synthase (Table 1). The low MW protein
region (<24kDa) did not yield suﬃciently signiﬁcant scores
for protein identiﬁcation with high conﬁdence. Rab3A [22,
23] was not identiﬁed although a faint band was seen
in the gel with a MW of about 20kDa. No signiﬁcant
protein (P<. 05)wasfoundforthis bandwhensearchingthe
database, however the hit returned was for a GTP-binding
protein.
To conﬁrm the ID of the newly identiﬁed proteins, we
conducted ESI-MS/MS on the trypsin digest of the bands.
Results were analyzed using Sequest software. The sequence
of the peptide was considered a positive hit if the cross-
correlation score (xCorr) was higher than 2 and the number
of matching ions higher than 60%. MS/MS results allowed
not only the conﬁrmation of the proteins previously iden-
tiﬁed by MALDI-TOF, but also the speciﬁc isoform of the
proteins interacting with MT-3 (see supplemental material,
Tables 2 and 3 available online at doi:10.4061/2011/208634).
Moreover, the MS/MS allowed for the detection of proteins
that were not conﬁdently detected with MALDI-TOF (val-
osin containing protein, HSP70 glucose-regulated protein
and protein 8, pyruvate kinase 3, tubulin alpha 3) each with
at least two peptides and an xCorr value higher than 2.
Table 1 summarizes the regrouped results of the MALDI-
TOF and MS/MS for all proteins identiﬁed and their known
function. This information allowed for the classiﬁcation of
the partner proteins into three groups: (1) proteins that
are involved in transport, (2) chaperoning/scaﬀolding and
regulation, and (3) glucose metabolism related proteins
(metabolic enzymes). A brief description of a representative
protein from each group is provided below.
3.1. Group 1: Exocyst Complex Component 8 (Exo84p).
Exo84p is a component of the exocyst multiprotein complex
that plays an important role in targeting and docking the
secretory vesicle, containing proteins and lipids, at the
plasma membrane [27]. The exocyst multiprotein com-
plex is composed of Sec3p, Sec5p, Sec6p, Sec8p, Sec10p,
Sec15p, Exo70p and Exo84p [28]. The exocyst complex
plays an essential role in tethering secretory vesicles to4 International Journal of Alzheimer’s Disease
speciﬁc domains of the plasma membrane for exocytosis
[29]. Exo84p plays a key role in the organization and the
polarized localization of the exocyst complex [29]. Exo84p
doesinteractwithSec5pand/orSec10p[27],proteinsthatwe
were not able to identify with conﬁdence in our data. Exo84p
can also interact with Ras and Ral GTPase proteins similar
to Rab3a [30]. The Ral-binding domain of Exo84p adopts
a plekstrin homology (PH) domain fold, which consists
of a seven-stranded β-sandwich containing two orthogonal
antiparallel β-sheets and an abutting C-terminal α-helix
[28].
3.2. Group 2: DRP-2/CRMP2. Dihydropyrimidinase-Related
Protein 2 (DRP-2) is a protein that is related to dihyropy-
rimidinase and is usually referred to as collapsing response
mediator protein (CRMP2). Five isoforms of CRMPs exists
in humans (CRMP1–CRMP5), which are approximately
70% identical to each other. There is no known enzymatic
activity for the DRP-2 protein family, although it is 58%
identical to the human dihydropyrimidinase that catalyzes
the second step in pyrimidine degradation. DRP-2 is known
to be involved in neuronal diﬀerentiation, axonal guidance
and neuronal polarity. The protein is highly expressed in
the developing nervous system. Overexpression of DRP-2
induces the growth of numerous axons and it is also involved
in the maturation of neurites and preexisting dendrites to
axons [31]. DRP-2 binds to tubulin heterodimers promoting
microtubule assembly [32]. However, this binding is inacti-
vatedbythephosphorylationofThr514byglycogensynthase
kinase 3β (GSK-3β)[ 33].
3.2.1. 14-3-3 Zeta. 14-3-3 proteins were ﬁrst identiﬁed in
1967 during a study of the soluble acidic proteins from
mammalian brains [34]. They are small proteins (∼30kDa)
that form both homo- and heterodimers. They include seven
isoforms in human cells. The importance of these proteins
was not recognized until later when it was discovered that
these proteins can activate tyrosine, tryptophan hydroxylases
and Raf and can inhibit protein kinase C [35]. 14-3-3 pro-
teins bind to speciﬁc phosphoserine or phosphothreonine
motifs (RSXpSXP and RXXXpSXP) in protein targets [36].
14-3-3 proteins can alter their target proteins using three
ways: (1) conformational change, (2) physical occlusion
of sequence-speciﬁc or structural protein features, and (3)
scaﬀolding [35]. They can, thereby, prevent the interaction
with other proteins, regulate the subcellular distribution of
proteins or protect proteins from proteolysis [37].
14-3-3 zeta modulates the action of proteins that are
involved in the cell cycle, transcriptional control, signal
transduction, intracellular traﬃcking and regulation of ion
channels [38]. Recently, 14-3-3 zeta was proposed to be a
“Sweeper” of misfolded proteins [39].
3.3. Group 3: Enolase. Enolase, also called 2-phospho-D-
glycerate hydrolase, is a metal-activated enzyme that cat-
alyzes the dehydration of 2-phospho-D-glycerate to phos-
phoenolpyruvate (pyruvate kinase substrate) [40]. In verte-
brates, three tissue-speciﬁc isoform are found: nonneuronal
Table 1: Proteins interacting with MT-3 identiﬁed with MALDI-
TOF and MS/MS, and their functions.
Protein ID MALDI-
TOF MS/MS Function
Exo84p x Transport
ATP synthase β subunit x x Transport
Valosin containing
protein x
HSP 84 x x Chaperoning
HSP70 glucose-regulated
protein x Chaperoning
HSP70 protein 8 x Chaperoning
Tubulin alpha 3 x Scaﬀold
γ-Actin x
β-Actin x x Scaﬀold
14-3-3 zeta x x Scaﬀold/regulation
Pyruvate kinase 3 x Glycolytic metabolism
γ-Enolase x Glycolytic metabolism
α-Enolase x x Glycolytic metabolism
Creatine Kinase BB x x Glycolytic metabolism
Aldolase 3 x
Aldolase 1 x x Glycolytic metabolism
Malate dehydrogenase x x Glycolytic metabolism
DRP-2 x x Neuronal growth
DRP-3 x
enolase (α), neuron-speciﬁc enolase (γ) and muscle-speciﬁc
enolase (β)[ 41]. Enolase exists in a physiological state as
a dimer, with the two monomer subunits oriented in an
antiparallel manner [40]. The dimerization process depends
on the two Mg2+ that are bound to the monomers and
the divalent metal ion plays a critical role in catalysis [40].
Although Mg2+ is the primary activator of enolase, the
enzyme also binds zinc strongly, which has a lower activity
[40].
Studies in yeast, vertebrates and mammalian cells have
shown that α-enolase may have other functions such as
thermal tolerance, growth control [42, 43], and hypoxia
tolerance [44]. Enolase also functions as a cell surface
receptor for plasminogen (PGn), which has a neurotrophic-
like eﬀect on neurons and enhances the neurite outgrowth of
neocortical explants [42, 43, 45].
The cellular localization of α-enolase is known to be
predominantly cytosolic [46] and can translocate to the
plasma membrane in either the homodimeric (αα)o r
heterodimeric (αγ) form. While the γ isoform is mainly
detected in cells of neuronal origin, the α isoform is widely
distributed among diﬀerent tissues [47]. The αα isoenzyme
(nonneuronal) is expressed in many tissues, while the ββ
isoenzyme occurs exclusively in muscle. The γγ isoenzyme
(neuronal) is present in neurons and neuroendocrine tissues
[48].
The αγ and γγ isoforms are the predominant dimers
in the brain, representing the neuron-speciﬁc enolases [49].International Journal of Alzheimer’s Disease 5
Speciﬁcally, the γ-type enolase subunit is mainly located in
neurons while α-type subunits are mostly found in glial cells
[49].
4. Discussion
MT-3 by itself is not toxic nor does it inhibit the growth
of neurons. Indeed, it maintains the survival of neurons in
culture [50]. MT-3 knockout mice show a higher suscep-
tibility to kainic acid induced neuronal injury, while mice
overexpressing MT-3 show enhanced resistance [51]. These
results suggest that MT-3 may play a neuroprotective role
against toxic substances. MT-3 is abundantly expressed in
astrocytes of normal brain [1, 52]. Moreover, when added
to neuronal cell cultures that are exposed to amyloid-β
peptides, MT-3 enhanced the resistance of the cells against
the amyloid-β toxicity. This activity is now known as the
MT-3 antiamyloid activity [53]. From these activities, one
can conclude that MT-3 needs to be secreted into the
extracellular milieu. Indeed, although MT-3 does not have
any signal sequence, a 23-day-old astrocytes cell culture did
secrete MT-3 into the media [50]. A recently published
results [24] showed a very important diﬀerence in the
secretion of MT-1 and 2 being triggered only in the presence
of Zn and Interleukin-1, neither of these factors have been
implicated in MT-3 secretion [50], which we propose is
mediated by one or more of the speciﬁc partner protein
interactions identiﬁed in this study.
The subcellular localization of MT-3 in rat brain astro-
cytes showed an association with organelles involved in
the secretion pathway-free ribosomes, rough endoplasmic
reticulum, small vesicles, the outer membrane of the
mitochondria, plasma membrane, and also around the
blood vessels [54]. The localization in neurons was mostly
found in the axons, dendrites, the synaptic vesicles, and
the postsynaptic densities [54]. It is, therefore, reasonable
to hypothesize that MT-3 may well be expressed in the
astrocytes. We propose that through its interaction with
some of the proteins that we have identiﬁed, MT-3 is
secreted to the extracellular milieu (blood vessels) and then
absorbed by the neurons. Strengthening this argument is the
fact that some of the proteins interacting with MT-3 are
in fact involved in the transport process: Rab3a, Exo84p.
Indeed, Exo84p is a subunit of the exocyst complex, which
is important in intracellular traﬃcking. In metazoa, Exo84p
has a PH domain towards its N-terminus. PH domains
share little sequence conservation, but all have a common
fold, which is electrostatically polarized. They are often
involved in targeting proteins to the plasma membrane,
with a few displaying strong speciﬁcity in lipid binding.
PH domains are found in cellular signaling proteins such
as serine/threonine kinase, tyrosine kinases, regulators of
G-proteins, endocytotic GTPases adaptors, as well as in
cytoskeletal associated molecules and in lipid-associated
enzymes. Exo84p can also interact with Ras and Ral GTPase
proteins similar to Rab3A [30]. Rabphilin3A, a downstream
eﬀector of Rab3A that binds the GTP-bound form of Rab3A
[55], also binds 14-3-3, another protein found in the MT-
3m u l t i p r o t e i nc o m p l e x[ 56]. 14-3-3 has also been shown
to interact with Sec23, a GTPase activating protein and a
component of the Sec23p-Sec24p heterodimeric complex of
the COPII vesicle coat, which is involved in ER to Golgi
transport in S. cerevisiae [57].
Based upon the above, a model for the secretion of
MT-3 is proposed. The secretion is regulated through the
“mitochondrial pathway” and involves MT-3’s interaction
with Rab3A, Exo84p and the exocyst complex, 14-3-3
zeta, and rabphilin3A (Figure 3, Left panel). Once MT-3 is
secreted, PGn and/or αγ-enolase could facilitate its uptake
by the neurons, which have been shown to uptake MT-1/2
[24]. Indeed, αγ-enolase is located on the cell surface of a
certainpopulationofneuronsandhasbeenshowntointeract
with the microglia-derived PGn, which has a neurotrophic-
like eﬀect on neurons [43].
TheneuronalMT-3couldthenregulatethegrowthofthe
neuronsthrougheitherorbothofthefollowingmechanisms:
(i) Considering that MT-3 has a GIF activity, one could
speculate that MT-3 might inhibit PGn. This may well be
facilitated through the common interacting protein enolase.
(ii) DRP-2 is known to regulate neuronal diﬀerentiation,
axonal guidance and neuronal polarity. Moreover, DRP-2
is involved in the maturation of neurites and preexisting
dendrites to axons, and its overexpression induces the
outgrowth of numerous axons [31]. On the other hand, MT-
3 suppresses the neurite extension of neurons in the early
period of diﬀerentiation and suppresses cell death of more
diﬀerentiated neurons [50]. Based on this, we hypothesize
thatthroughitsinteractionwithDRP-2,MT-3couldregulate
the growth of the neurons (Figure 3, right panel).
The above model conforms to the neuroactivity of MT3
and its reported reduction in AD brain tissue [52], where
the above regulatory interactions would be disrupted. The
trigger might well be the oxidative stress or other hallmark
pathology associated with the disease: the neuroﬁbrillary
tangles or the plaques. Most proteins found in the mul-
tiprotein complex(es) with MT3 have in fact been shown
to be altered in AD patients. 14-3-3 zeta is overexpressed
in the temporal cortex of patient with cognitive impair-
ment, leading to its implication in the AD neuropathology
[58]. Glyceraldehyde-3-phosphate dehydrogenase, pyruvate
kinase, malate dehydrogenase and 14-3-3 zeta were found to
besigniﬁcantlyoxidizedbothinratbrainsandincellcultures
that were exposed to amyloid-β42 [59, 60]. γ-enolase and
malate dehydrogenase were found to be downregulated in
the Tg2576 AD mouse model, whereas pyruvate kinase, α-
enolase, and DRP-2 were upregulated [61]. The expression
of DRP-2 in the hippocampal neurons promotes axon
elongation. This latter function seems to depend upon the
phosphorylation of DRP-2 by GSK-3β [31, 32, 62, 63].
14-3-3 zeta has been proposed to be an eﬀector of tau
phosphorylationbyGSK-3β andhyperphosphorylatedDRP-
2 has been detected within neuroﬁbrillary tangles from the
brains of Alzheimer’s disease patients [62, 64]. The hyper-
phosphorylation of DRP-2 could inhibit the interaction with
MT-3 leading to the alteration of the GIF activity of MT-
3 and, therefore, to the outgrowth of the neurons. It is
noteworthy, to reemphasize the positive correlation found
between the GIF activity and the neuroﬁbrillary tangles [3].6 International Journal of Alzheimer’s Disease
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Figure 3: Schematic model of the interactions of MT-3 and its implication on the biological functions of MT-3. The hypothetical model
describes the process of secretion of MT-3, from the astrocytes into the extracellular milieu, through its interaction with Rab3A, 14-3-3 zeta,
Exo84p (Left panel). The uptake of MT-3 into the neurons and their growth regulation: uptake is facilitated through the interaction with
the plasminogen (PGn) and enolase (either, αγ or γγ). Once inside the neurons, MT-3 protects the neurons from the extension and the
outgrowth through its interaction with DRP-2. In Alzheimer’s disease, oxidative stress alters several proteins involved in the interaction with
MT-3, therefore potentially aﬀecting the pathway of secretion and/or the uptake.
To summarize, novel new partner proteins for MT3
have been identiﬁed. The identities of a couple of these
associated proteins, 14-3-3 and Exo84p, provide a basis for
a biologically relevant model for the processing of MT3.
In view of the size of MT3, we favor an interaction model
involvingmultipleinteractionsasopposedtosinglecomplex.
The interaction model we envision is a thiol/disulﬁde
interchange model, which could involve one or more of the
many cysteines in MT3. Indeed, Rab3A, 14-3-3Z, Exo84p,
α-enolase, all have cysteines that could participate in thisInternational Journal of Alzheimer’s Disease 7
thiol/disulﬁde interchange model. In this regard, it is impor-
tant to note that published work [65] has established that the
beta domain of MT3 binds 4 copper leaving two cysteines
free to participate in such a mechanism. This is in contrast
to MT1 and 2, both of which bind either 3 zinc or 6 coppers
to the beta domain leaving no free cysteines to participate
in such a thiol exchange mechanism. The proposed model,
along with Rab3A [22, 23], promotes the secretion of MT3
from astrocytes. Now in the extracellular milieu, MT-3 is
positioned to function consistent with its reported activities:
the regulation of neuronal growth and the antagonism
of β-amyloid. Regulation of the growth of neurons could
be mediated through two possible mechanisms: (i) direct
inhibition of the PGn at the surface of neurons, or (ii) the
uptake of MT3 into neurons facilitated by the interaction
with enolase located in the cell surface of the neurons.
Once taken up by the neurons, MT-3 could then regulate
the growth of neurons through its association with DRP-
2. Further studies are in progress to validate this newly
proposed functional model for MT3’s role in regulating
neuronal growth.
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